The facts

  1. Full-year reported sales growth is now expected to be approximately 4.25%, with organic growth of about 3.75%. Previous ranges were 5.5–6.5% and 5–6%, respectively. [1][2]

  2. Annual adjusted earnings are now forecast at US$3.16–3.18 a share, against the previous US$3.28–3.32 range. These are non-GAAP figures. [1][2]

  3. Quarterly sales increased 1.5%. GAAP net income fell to US$582 million from US$755 million; diluted earnings were US$0.40 versus US$0.51. [1]

  4. Adjusted quarterly earnings were US$0.73 a share, compared with US$0.75. The company expects fourth-quarter sales to fall 1–3% on both reported and organic bases. [1]

Sources

References support the numbered facts above. Source checks: 29 Oct 2026, 13:55 UTC.

  1. Boston Scientific announces results for third quarter 2026

    Boston Scientific · Primary source · 28 Oct 2026

    Actual company results, current guidance and CEO’s description of cyber-related operational recovery read.

  2. Boston Scientific again trims FY26 outlook

    RTTNews · Reporting · 28 Oct 2026

    Independent report establishes comparison with the previous annual forecast.

Report a factual error